Every blockbuster drug losing US exclusivity from 2025 to 2037 in one sourced spreadsheet: 63 drugs with $433B in 2025 sales, 199 generic and biosimilar makers, company exposure, launch erosion and Medicare prices. Every row links to its primary source.
Built for business development, strategy and investment teams who would otherwise copy this off dozens of pages. Free to use internally and to cite with a link.
Data checked 8 October 2026. Excel file; works in Google Sheets and Numbers.
| Drug | US LOE | Date basis | 2025 sales | US copies | Medicare |
|---|---|---|---|---|---|
| KeytrudaMerck | 2028 | Company guidance | $31.7B | In clinical trials6 makers tracked | – |
| EliquisBristol Myers Squibb / Pfizer | 2028 | Settlement / court date | $14.4B | Approved, waiting to launch6 makers tracked | 2026 · −56% |
| OzempicNovo Nordisk | 2032 | Company guidance | ≈$19.3B | Filed with the FDA7 makers tracked | 2027 · −71% |
| XolairRoche / Novartis | 2026 | Biosimilars launched | ≈$5.4B | Copies on the US market2 makers tracked | 2028 |
| EntrestoNovartis | 2025 | Generics launched | $7.7B | Copies on the US market16 makers tracked | 2026 · −53% |
5 of 63 rows. In the spreadsheet every row also carries the sales booked by each company, a copy summary, notes and source links.
Quarterly updates and a team licence. Tell us in the form whether you'd pay for it; it decides whether we build it.
Where does the data come from? Company 10-K, 10-Q, 20-F and annual reports, the FDA Orange Book and Purple Book, CMS fact sheets and court records. Every row links to its source, and the same data drives this site.
Can I use it at work? Yes. The Founding edition, Q4 2026 is free to use internally and to cite with a link to pharmapatentcliff.com. Please don't republish the dataset as a whole.
How often is it updated? The site is updated as things change. The full edition will be refreshed every quarter.